M JAMES BARRETT
CIK 1219855 · last filed 2019-06-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$22.84B
Companies
48
Total Filings
222
Lifetime Open-Market Net
-$266.46M
Filer Profile
Reported Address
1119 ST PAUL STREETBALTIMORE, MD 21202
Related Filers
PETER J BARRIS — 74 joint filings, latest 2018-10-24
SCOTT D SANDELL — 71 joint filings, latest 2018-10-24
NEA PARTNERS 10 L P — 43 joint filings, latest 2018-07-31
MARK W PERRY — 41 joint filings, latest 2012-05-16
C RICHARD KRAMLICH — 39 joint filings, latest 2012-05-16
CHARLES W NEWHALL III — 39 joint filings, latest 2012-05-16
ENTERPRISE ASSOCIATES 10 L P NEW — 37 joint filings, latest 2018-08-08
III EUGENE A TRAINOR — 31 joint filings, latest 2009-11-13
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SENS | Director | 33,240 | $8.88 | $295.0K | $14.50M | 12 | 2019-06-03 |
| Clovis Oncology, Inc. (CLVS) Delisted | Director | 12,260 | $0.08 | $996 | $16.54M | 11 | 2018-10-15 |
| ASND | 10%+ Owner | 82,978,668 | $263.21 | $21.84B | $29.01M | 4 | 2018-09-10 |
| KINETA, INC./DE (PTI) Delisted | Director | 277,730 | — | — | $23.20M | 6 | 2018-06-19 |
| ARDX | 10%+ Owner | 9,169,210 | $3.53 | $32.37M | $31.61M | 5 | 2018-05-30 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Director | 49,957 | $15.70 | $784.3K | $7.83M | 8 | 2018-05-21 |
| Surface Oncology, Inc. (SURF) Delisted | 10%+ Owner | 3,179,544 | $1.07 | $3.40M | $2.00M | 1 | 2018-04-23 |
| TESARO, Inc. (TSRO) Delisted | 10%+ Owner | 9,597,639 | — | — | $46.41M | 7 | 2018-03-06 |
| APPN | 10%+ Owner | 676 | $38.10 | $25.8K | -$66.07M | 4 | 2018-02-15 |
| SYNLOGIC, INC. (SYBX) Delisted | 10%+ Owner | 281,929 | $0.69 | $194.5K | $0 | 2 | 2018-01-26 |
| Care.com Inc (CRCM) Delisted | 10%+ Owner | 2,256,265 | — | — | $0 | 2 | 2017-11-08 |
| RYTM | 10%+ Owner | 4,359,956 | $102.33 | $446.13M | $9.35M | 1 | 2017-10-10 |
| Mersana Therapeutics, Inc. (MRSN) Delisted | 10%+ Owner | 325,606 | $29.08 | $9.47M | $15.00M | 1 | 2017-07-06 |
| Roka BioScience, Inc. (ROKA) Delisted | Director | 321,681 | — | — | $4.60M | 6 | 2017-06-30 |
| MULESOFT, INC (MULE) Delisted | 10%+ Owner | 12,679,970 | — | — | $0 | 1 | 2017-03-22 |
| Zosano Pharma Corp (ZSAN) Delisted | 10%+ Owner | 1,361 | $0.56 | $759 | -$2.06M | 8 | 2017-02-14 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | 10%+ Owner | 80,223 | — | — | $4.39M | 1 | 2016-10-31 |
| SUPN | Director | 130,715 | $41.60 | $5.44M | $12.39M | 14 | 2016-03-24 |
| Epizyme, Inc. (EPZM) Delisted | 10%+ Owner | 406,825 | $1.47 | $598.0K | $23.85M | 4 | 2016-01-12 |
| Avalo Therapeutics, Inc. (CERC.U) Delisted | 10%+ Owner | 594,245 | — | — | $0 | 1 | 2015-10-20 |
| SYNLOGIC, INC. (MIRN) Delisted | 10%+ Owner | 1,241,650 | — | — | $6.00M | 1 | 2015-10-06 |
| Loxo Oncology, Inc. (LOXO) Delisted | Director | 1,789,420 | — | — | $3.00M | 3 | 2015-07-30 |
| Vitae Pharmaceuticals, Inc (VTAE) Delisted | 10%+ Owner | 1,598 | — | — | $0 | 1 | 2015-07-02 |
| BOX | 10%+ Owner | 2,091,457 | $34.88 | $72.95M | $0 | 1 | 2015-01-29 |
| BOINGO WIRELESS, INC. (WIFI) Delisted | 10%+ Owner | 3,569,210 | $13.99 | $49.93M | -$6.47M | 4 | 2014-12-22 |
| Tableau Software Inc (DATA) Delisted | 10%+ Owner | 1,270,522 | — | — | -$100.09M | 10 | 2014-12-04 |
| CVENT INC (CVT) Delisted | 10%+ Owner | 2,891 | $8.52 | $24.6K | -$46.32M | 5 | 2014-11-28 |
| DERM | 10%+ Owner | 3,433,810 | $7.40 | $25.41M | $1.11M | 1 | 2014-10-08 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | 10%+ Owner | 294,500 | $18.62 | $5.48M | $58.68M | 3 | 2014-08-29 |
| AUDIENCE INC (ADNC) Delisted | 10%+ Owner | 14,898 | — | — | -$70.0K | 4 | 2013-11-06 |
| XOOM Corp (XOOM) Delisted | 10%+ Owner | 1,185 | — | — | $0 | 1 | 2013-10-31 |
| GRPN | 10%+ Owner | 2,359 | $19.12 | $45.1K | -$307.2K | 2 | 2013-09-17 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Director | 4,584,311 | $14.49 | $66.43M | $5.27M | 5 | 2013-06-17 |
| WDAY | 10%+ Owner | 586 | $194.40 | $113.9K | $0 | 2 | 2013-04-11 |
| Millennial Media Inc. (MM) Delisted | 10%+ Owner | 8,196,614 | — | — | -$21.48M | 2 | 2012-10-30 |
| FUSION-IO, INC. (FIO) Delisted | 10%+ Owner | 9,039,712 | — | — | -$43.39M | 15 | 2012-09-20 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | 10%+ Owner | 1,590,142 | — | — | $5.00M | 1 | 2012-08-02 |
| INNERWORKINGS INC (INWK) Delisted | 10%+ Owner | 15,000 | — | — | -$12.63M | 8 | 2012-03-30 |
| ECHO | 10%+ Owner | 2,020,338 | $93.61 | $189.12M | -$2.2K | 1 | 2012-03-01 |
| INHIBITEX, INC. (INHX) Delisted | Director | 2,009,899 | — | — | $3.00M | 9 | 2012-02-03 |
| GLU MOBILE INC (GLUU) Delisted | 10%+ Owner | 5,919,443 | $12.50 | $73.99M | $0 | 1 | 2011-08-09 |
| VG | 10%+ Owner | 14,061,581 | $15.28 | $214.79M | $0 | 1 | 2011-03-15 |
| SOURCEFIRE INC (FIRE) Delisted | 10%+ Owner | 2,691,813 | — | — | -$56.19M | 1 | 2009-05-05 |
| INTERCELL USA, INC. (IOMI) Delisted | Director | 0 | — | — | $0 | 4 | 2008-08-06 |
| TNDM | 10%+ Owner | 544,618 | $16.62 | $9.05M | -$15.43M | 1 | 2008-04-24 |
| PHARMION CORP (PHRM) Delisted | Director | 105,560 | — | — | $0 | 5 | 2008-02-28 |
| Data Domain, Inc. (DDUP) Delisted | 10%+ Owner | 11,835,312 | — | — | -$218.68M | 2 | 2007-12-05 |
| MEDI | Director | 0 | $33.70 | $0 | $0 | 1 | 2007-06-19 |
Recent Filings · Page 9 of 23
222 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-06-17 | SUPN | Mixed | −2,823,071 | -$928.7K | EDGAR |
| 2015-06-15 | Clovis Oncology, Inc. (CLVS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-09 | ARDX | Buy (P) | +1,869,159 | $20.00M | EDGAR |
| 2015-06-04 | TESARO, Inc. (TSRO) Delisted | Sell (S) | −2,129 | -$122.9K | EDGAR |
| 2015-06-02 | TESARO, Inc. (TSRO) Delisted | Other (J) | −997,367 | $0 | EDGAR |
| 2015-05-15 | Clovis Oncology, Inc. (CLVS) Delisted | Mixed | −1,139,317 | -$224.0K | EDGAR |
| 2015-05-11 | — | U | −2,384,221 | -$109.67M | |
| 2015-03-05 | SUPN | Grant (A) | — | $0 | EDGAR |
| 2015-02-05 | — | Mixed | +1,888,474 | $5.00M | |
| 2015-02-02 | Zosano Pharma Corp (ZSAN) Delisted | Mixed | +364,658 | $3.45M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.